{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:45:19Z","timestamp":1790383519907,"version":"4.1.0"},"reference-count":46,"publisher":"Georg Thieme Verlag KG","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2014]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Even 10 years after the first appearance in the literature of articles reporting on the management of patients on oral anticoagulation (OAC) undergoing percutaneous coronary intervention with stent (PCI-S), this issue is still controversial. Nonetheless, some guidance for the everyday management of this patient subset, accounting for about 5\u20138 % of all patients referred for PCI-S, has been developed. In general, a period of triple therapy (TT) of OAC, with either vitamin K\u2013antagonists (VKA) or non-vitamin K\u2013antagonist oral anticoagulants (NOAC), aspirin, and clopidogrel is warranted, followed by the combination of OAC, and a single antiplatelet agent for up to 12 months, and then OAC alone. The duration of the initial period of TT is dependent on the individual risk of thromboembolism, and bleeding, as well as the clinical context in which PCI-S is performed (elective vs acute coronary syndrome), and the type of stent implanted (bare-metal vs drug-eluting). In this article, we aim to provide a comprehensive, ata- glance, overview of the management strategies, which are currently suggested for the peri-procedural, medium-term, and long-term periods following PCI-S in OAC patients. While acknowledging that most of the evidence has been obtained from patients on OAC because of atrial fibrillation, and with warfarin being the most frequently used VKA, we refer in this overview to the whole population of OAC patients undergoing PCI-S. We refer to the whole population of patients on OAC undergoing PCI-S also when OAC is carried out with NOAC rather than VKA, pointing out, when appropriate, the particular management issues.<\/jats:p>\n                  <jats:p>Note: The review process for this paper was fully handled by Christian Weber, Editor-in-Chief.<\/jats:p>","DOI":"10.1160\/th14-08-0681","type":"journal-article","created":{"date-parts":[[2014,10,9]],"date-time":"2014-10-09T04:45:17Z","timestamp":1412829917000},"page":"1080-1087","source":"Crossref","is-referenced-by-count":46,"title":["The optimal management of patients on oral anticoagulation undergoing coronary artery stenting"],"prefix":"10.1160","volume":"112","author":[{"given":"David","family":"Faxon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhani","family":"Airaksinen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Schlitt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Mar\u00ecn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Bhatt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Lip","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Rubboli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2017,11,17]]},"reference":[{"key":"10.1160\/TH14-08-0681-1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2003.06.004"},{"key":"10.1160\/TH14-08-0681-2","first-page":"851","volume":"5","author":"Rubboli","year":"2004","journal-title":"Ital Heart J"},{"key":"10.1160\/TH14-08-0681-3","first-page":"919","volume":"5","author":"Rubboli","year":"2004","journal-title":"Ital Heart J"},{"key":"10.1160\/TH14-08-0681-4","doi-asserted-by":"publisher","DOI":"10.1080\/07853890802089786"},{"key":"10.1160\/TH14-08-0681-5","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-08-0580"},{"key":"10.1160\/TH14-08-0681-6","doi-asserted-by":"publisher","DOI":"10.1160\/TH11-04-0262"},{"key":"10.1160\/TH14-08-0681-7","unstructured":"Lip GY, Windecker S, Huber K, et al. Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting With\u00a0Acute Coronary Syndrome and\/or Undergoing Percutaneous Coronary or Valve\u00a0Interventions: A joint Consensus Document of the European Society of Cardiology\u00a0Working Group on Thrombosis, European Heart Rhythm Association [EHRA], European\u00a0Association of Percutaneous Cardiovascular Interventions [EAPCI] and European\u00a0Association of Acute Cardiac Care [ACCA].\u00a0Endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 2014; in press"},{"key":"10.1160\/TH14-08-0681-8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehn099"},{"key":"10.1160\/TH14-08-0681-9","doi-asserted-by":"crossref","unstructured":"Lahtela H, Rubboli A, Schlitt A, et al.; AFCAS (Management of patients with Atrial Fibrillation undergoing Coronary Artery Stenting) study group. Heparin bridging vs uninterrupted oral anticoagulation in patients with Atrial Fibrillation undergoing Coronary Artery Stenting. Results from the AFCAS registry. Circ J 2012; 76: 1363-1368","DOI":"10.1253\/circj.CJ-11-1206"},{"key":"10.1160\/TH14-08-0681-10","doi-asserted-by":"crossref","unstructured":"Dewilde WJ, Janssen PW, Kelder JC, et al. Uninterrupted oral anticoagulation versus bridging in patients with long-term oral anticoagulation during percutaneous coronary intervention: subgroup analysis from the WOEST trial. Eurointervention 2014; Epub ahead of print","DOI":"10.4244\/EIJY14M06_07"},{"key":"10.1160\/TH14-08-0681-11","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2298"},{"key":"10.1160\/TH14-08-0681-12","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2013.09.043"},{"key":"10.1160\/TH14-08-0681-13","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2012.02.045"},{"key":"10.1160\/TH14-08-0681-14","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eut083"},{"key":"10.1160\/TH14-08-0681-15","doi-asserted-by":"publisher","DOI":"10.4244\/EIJV8I9A162"},{"key":"10.1160\/TH14-08-0681-16","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.22527"},{"key":"10.1160\/TH14-08-0681-17","doi-asserted-by":"crossref","unstructured":"Hamon M, Pristipino C, Di Mario C, et al.; European Association of Percutaneous Cardiovascular Interventions; Working Group on Acute Cardiac Care of the European Society of Cardiology; Working Group on Thrombosis on the European Society of Cardiology. Consensus document on the radial approach in percutaneous cardiovascular interventions: position paper by the European Association of Percutaneous Cardiovascular Interventions and Working Groups on Acute Cardiac Care and Thrombosis of the European Society of Cardiology. Eurointervention 2013; 8: 1242-1251","DOI":"10.4244\/EIJV8I11A192"},{"key":"10.1160\/TH14-08-0681-18","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu278"},{"key":"10.1160\/TH14-08-0681-19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60324-9"},{"key":"10.1160\/TH14-08-0681-20","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu026"},{"key":"10.1160\/TH14-08-0681-21","doi-asserted-by":"crossref","unstructured":"King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, et al. 2007 focused update of the ACC\/AHA\/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines: (2007 Writing Group To Review New Evidence and Update the 2005 ACC\/AHA\/SCAI Guideline Update for Percutaneous Coronary Intervention. Circulation 2008; 117; 265-291","DOI":"10.1161\/CIRCULATIONAHA.107.188208"},{"key":"10.1160\/TH14-08-0681-22","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1160\/TH09-04-0245","volume":"102","author":"Lahtela","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1160\/TH14-08-0681-23","doi-asserted-by":"crossref","unstructured":"Stone GW, Witzenbichler B, Guagliumi G, et al.; HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358: 2218-2230","DOI":"10.1056\/NEJMoa0708191"},{"key":"10.1160\/TH14-08-0681-24","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2014.01.038"},{"key":"10.1160\/TH14-08-0681-25","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.113.000415"},{"key":"10.1160\/TH14-08-0681-26","doi-asserted-by":"crossref","unstructured":"Wiviott SD, Braunwald E, McCabe CH, et al.; TRITON TIMI-38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015","DOI":"10.1056\/NEJMoa0706482"},{"key":"10.1160\/TH14-08-0681-27","doi-asserted-by":"crossref","unstructured":"Wallentin L, Becker RC, Budaj A, et al.; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057","DOI":"10.1056\/NEJMoa0904327"},{"key":"10.1160\/TH14-08-0681-28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.02.036"},{"key":"10.1160\/TH14-08-0681-29","doi-asserted-by":"publisher","DOI":"10.1160\/TH13-04-0351"},{"key":"10.1160\/TH14-08-0681-30","doi-asserted-by":"publisher","DOI":"10.1160\/TH12-08-0542"},{"key":"10.1160\/TH14-08-0681-31","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.115386"},{"key":"10.1160\/TH14-08-0681-32","doi-asserted-by":"publisher","DOI":"10.1160\/TH13-06-0443"},{"key":"10.1160\/TH14-08-0681-33","doi-asserted-by":"publisher","DOI":"10.1160\/TH13-07-0556"},{"key":"10.1160\/TH14-08-0681-34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.08.002"},{"key":"10.1160\/TH14-08-0681-35","doi-asserted-by":"publisher","DOI":"10.1160\/TH13-02-0150"},{"key":"10.1160\/TH14-08-0681-36","doi-asserted-by":"crossref","unstructured":"Dewilde WJ, Oirbans T, Verheugt FW, et al.; WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013; 381: 1107-1115","DOI":"10.1016\/S0140-6736(12)62177-1"},{"key":"10.1160\/TH14-08-0681-37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.05.029"},{"key":"10.1160\/TH14-08-0681-38","doi-asserted-by":"crossref","unstructured":"Rubboli A, Schlitt A, Kiviniemi T, et al.; AFCAS Study Group. One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting: an analysis of the AFCAS registry. Clin Cardiol 2014; 37: 357-364","DOI":"10.1002\/clc.22254"},{"key":"10.1160\/TH14-08-0681-39","unstructured":"Rubboli A, Saia F, Sciahbasi A, et al; WAR-STENT Study Group. Outcome of patients on oral anticoagulation undergoing coronary artery stenting: data from discharge to 12 months in the WARfarin and coronary STENTing (WAR-STENT) Registry. J Invasive Cardiol 2014; in press"},{"key":"10.1160\/TH14-08-0681-40","unstructured":"US National Institutes of Health, ClinicalTrials.gov. A study exploring two strategies of rivaroxaban (JNJ39039039; BAY-59-7939) and one of oral vitamin K antagonist in patients with atrial fibrillation who undergo percutaneous coronary intervention. http\/\/clinicaltrials.gov\/ct2\/show. Accessed August 14, 2014"},{"key":"10.1160\/TH14-08-0681-41","unstructured":"US National Institutes of Health, ClinicalTrials.gov. Evaluation of dual therapy with dabigatran vs triple therapy with warfarin in patients with AF who undergo PCI with stenting (RE-DUAL PCI). http\/\/clinicaltrials.gov\/ct2\/show. Accessed August 14, 2014"},{"key":"10.1160\/TH14-08-0681-42","doi-asserted-by":"publisher","DOI":"10.1159\/000086918"},{"key":"10.1160\/TH14-08-0681-43","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehl488"},{"key":"10.1160\/TH14-08-0681-44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020496"},{"key":"10.1160\/TH14-08-0681-45","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61751-7"},{"key":"10.1160\/TH14-08-0681-46","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000515"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1160\/th14-08-0681.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T21:31:59Z","timestamp":1565904719000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1160\/th14-08-0681"}},"subtitle":["The 10th Anniversary Overview"],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":46,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2017,11,29]]},"published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1160\/th14-08-0681","relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}